Correlation between brain dopamine levels and 1-dopa activity in anti-Parkinson tests.
D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology*; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001763:Blepharoptosis / Q000139:chemically induced; D001921:Brain / Q000378:metabolism*; D002389:Catatonia / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000032:analysis / Q000494:pharmacology*; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D005334:Fever / Q000139:chemically induced; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009638:Norepinephrine / Q000032:analysis; D010095:Oxotremorine / Q000037:antagonists & inhibitors; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D012110:Reserpine / Q000037:antagonists & inhibitors; D013997:Time Factors; D014202:Tremor / Q000139:chemically induced
D000978:Antiparkinson Agents; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D006834:Hydrazines; D010095:Oxotremorine; D004295:Dihydroxyphenylalanine; D012110:Reserpine; D004298:Dopamine; D009638:Norepinephrine